HRP20150584T1 - Soli i polimorfi tetraciklinskog spoja - Google Patents
Soli i polimorfi tetraciklinskog spoja Download PDFInfo
- Publication number
- HRP20150584T1 HRP20150584T1 HRP20150584TT HRP20150584T HRP20150584T1 HR P20150584 T1 HRP20150584 T1 HR P20150584T1 HR P20150584T T HRP20150584T T HR P20150584TT HR P20150584 T HRP20150584 T HR P20150584T HR P20150584 T1 HRP20150584 T1 HR P20150584T1
- Authority
- HR
- Croatia
- Prior art keywords
- solvents
- combination
- polymorph
- radiation
- compound
- Prior art date
Links
- 239000004098 Tetracycline Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 229960002180 tetracycline Drugs 0.000 title 1
- 229930101283 tetracycline Natural products 0.000 title 1
- 235000019364 tetracycline Nutrition 0.000 title 1
- -1 tetracycline compound Chemical class 0.000 title 1
- 239000002904 solvent Substances 0.000 claims 20
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 13
- 238000000034 method Methods 0.000 claims 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 9
- 230000005855 radiation Effects 0.000 claims 9
- 229940125904 compound 1 Drugs 0.000 claims 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 230000001476 alcoholic effect Effects 0.000 claims 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000010802 sludge Substances 0.000 claims 2
- PFCHFHIRKBAQGU-UHFFFAOYSA-N 3-hexanone Chemical compound CCCC(=O)CC PFCHFHIRKBAQGU-UHFFFAOYSA-N 0.000 claims 1
- 239000012296 anti-solvent Substances 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
- C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
- C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
- C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
- C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Seasonings (AREA)
Claims (19)
1. Kristalni oblik, naznačen time što je kristalni oblik tosilatne soli Spoja 1:
[image]
.
2. Polimorf kristalnog oblika u skladu s patentnim zahtjevom 1, naznačen time što je za njega karakterističan uzorak difrakcije rendgenskih zraka na prahu sa signalima na približno 8,06, 13,02, te 18,83 °2θ uz upotrebu zračenja Cu Kα, ili signalima na približno 8,06, 11,41, 13,02, 18,83, 20,54, te 24,53 °2θ uz upotrebu zračenja Cu Kα, ili signalima na približno 5,60, 8,06, 8,57, 11,41, 13,02, 15,58, 18,83, 20,54 i 24,53 °2θ uz upotrebu zračenja Cu Kα, ili uzorak difrakcije rendgenskih zraka na prahu uglavnom sličan onom prikazanom na Slici 8.
3. Polimorf u skladu s patentnim zahtjevom 2, naznačen time što se dobiva kristaliziranjem tosilatne soli Spoja 1:
[image]
iz izopropanola.
4. Postupak priprave stabilne kristalne tosilatne soli Spoja 1:
[image]
,
naznačen time što se postupak sastoji u:
otapanju slobodne baze Spoja 1 u prvom otapalu ili kombinaciji otapala kako bi se dobilo prvu otopinu;
otapanju p-toluensulfonske kiseline u drugom otapalu ili kombinaciji otapala kako bi se dobilo drugu otopinu;
kombiniranju prve s drugom otopinom kako bi se dobilo treću otopinu; i
dodavanju oblika 1 polimorfa tosilatne soli Spoja 1 kao kristala za zasijavanje u treću otopinu kako bi se dobilo četvrtu otopinu.
5. Postupak u skladu s patentnim zahtjevom 4, naznačen time što su prvo otapalo ili kombinacija otapala i drugo otapalo ili kombinacija otapala ista ili različita.
6. Postupak u skladu s patentnim zahtjevom 4, naznačen time što je svaka od prve kombinacije otapala i druge kombinacije otapala neovisno kombinacija alkoholnih otapala.
7. Postupak u skladu s patentnim zahtjevom 6, naznačen time što je svaka od prve kombinacije otapala i druge kombinacije otapala neovisno kombinacija dva alkoholna otapala, što dva alkoholna otapala mogu biti etanol i izopropanol, gdje, primjerice, etanol i izopropanol mogu biti u volumnom omjeru od 2 prema 1.
8. Postupak u skladu s patentnim zahtjevom 4, naznačen time što svaka od prve kombinacije otapala i druge kombinacije otapale sadrži alkoholno otapalo, koje može biti metanol, te protuotapalo, koje se može birati između ketona, estera i etera (primjerice metil-t-butil-etera).
9. Postupak u skladu s patentnim zahtjevom 4, naznačen time što svaka od prve kombinacije otapala i druge kombinacije otapale sadrži metanol i metil-t-butil-eter, te što metanol i metil-t-butil-eter mogu biti u volumnom omjeru od 1 do 1,2.
10. Postupak u skladu s patentnim zahtjevom 4, naznačen time što se p-toluensulfonsku kiselinu dodaje u količini od 25 do 75%, težinski, u odnosu na količinu navedenog Spoja 1.
11. Postupak u skladu s patentnim zahtjevom 4, naznačen time što se p-toluensulfonsku kiselinu dodaje u obliku monohidrata p-toluensulfonske kiseline.
12. Postupak u skladu s patentnim zahtjevom 4, naznačen time što četvrta otopina daje mulj prilikom miješanja, te što postupak može dodatno uključivati sušenje mulja.
13. Polimorf tosilatne soli Spoja 1:
[image]
,
naznačen time što se dobiva postupkom u skladu s patentnim zahtjevom 4.
14. Polimorf kristalnog oblika u skladu s patentnim zahtjevom 1, naznačen time što je za njega karakterističan uzorak difrakcije rendgenskih zraka na prahu sa signalima na približno 5,11 i 15,60 °2θ uz upotrebu zračenja Cu Kα, ili signalima na približno 5,11, 8,89, 10,34, 11,76, te 15,60 °2θ uz upotrebu zračenja Cu Kα, ili signalima na približno 5,11, 8,89, 10,34, 11,76, 13,70, 14,81, te 15,60 °2θ uz upotrebu zračenja Cu Kα, ili uzorak difrakcije rendgenskih zraka na prahu uglavnom sličan onom prikazanom na Slici 10.
15. Polimorf kristalnog oblika u skladu s patentnim zahtjevom 1, naznačen time što je za njega karakterističan uzorak difrakcije rendgenskih zraka na prahu sa signalima na približno 11,88 i 16,12 °2θ uz upotrebu zračenja Cu Kα, ili signalima na približno 7,82, 11,88, 16,12, te 21,46 °2θ uz upotrebu zračenja Cu Kα, ili signalima na približno 7,82, 11,88, 12,68, 16,12, 18,63, 21,46, te 23,74 °2θ uz upotrebu zračenja Cu Kα, ili uzorak difrakcije rendgenskih zraka na prahu uglavnom sličan onom prikazanom na Slici 9.
16. Polimorf u skladu s patentnim zahtjevom 14, naznačen time što se dobiva kristaliziranjem tosilatne soli Spoja 1:
[image]
iz acetona, metil-etil-ketona, metilpentanona ili etil-acetata.
17. Polimorf u skladu s patentnim zahtjevom 15, naznačen time što se dobiva kristaliziranjem tosilatne soli Spoja 1:
[image]
iz diklormetana.
18. Farmaceutski pripravak, naznačen time što sadrži kristalni oblik u skladu s patentnim zahtjevom 1 ili polimorf u skladu s bilo kojim od patentnih zahtjeva 2 i 13-15, kao i farmaceutski prihvatljivi razrjeđivač, pomoćnu tvar ili podlogu.
19. Farmaceutski pripravak u skladu s patentnim zahtjevom 18, naznačen time što je polimorf u čistom obliku.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12871208P | 2008-05-23 | 2008-05-23 | |
| EP09751737.9A EP2296464B1 (en) | 2008-05-23 | 2009-05-26 | Salts and polymorphs of a tetracycline compound |
| PCT/US2009/045143 WO2009143509A1 (en) | 2008-05-23 | 2009-05-26 | Salts and polymorphs of a tetracycline compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150584T1 true HRP20150584T1 (hr) | 2015-07-03 |
Family
ID=41340587
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150584TT HRP20150584T1 (hr) | 2008-05-23 | 2015-06-02 | Soli i polimorfi tetraciklinskog spoja |
| HRP20202081TT HRP20202081T1 (hr) | 2008-05-23 | 2020-12-31 | Soli i polimorfi tetraciklinskog spoja |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20202081TT HRP20202081T1 (hr) | 2008-05-23 | 2020-12-31 | Soli i polimorfi tetraciklinskog spoja |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US8383610B2 (hr) |
| EP (3) | EP2296464B1 (hr) |
| JP (6) | JP5727930B2 (hr) |
| KR (1) | KR101679362B1 (hr) |
| CN (4) | CN104844472B (hr) |
| AR (1) | AR075447A1 (hr) |
| AU (2) | AU2009248795B2 (hr) |
| BR (1) | BRPI0913026B1 (hr) |
| CA (2) | CA2724897C (hr) |
| CO (1) | CO6300898A2 (hr) |
| CY (2) | CY1116436T1 (hr) |
| DK (2) | DK2296464T3 (hr) |
| EC (1) | ECSP10010704A (hr) |
| ES (2) | ES2842204T3 (hr) |
| HK (2) | HK1204526A1 (hr) |
| HR (2) | HRP20150584T1 (hr) |
| HU (1) | HUE053038T2 (hr) |
| IL (1) | IL209414A0 (hr) |
| LT (1) | LT2807926T (hr) |
| MA (1) | MA32407B1 (hr) |
| MX (1) | MX2010012622A (hr) |
| MY (1) | MY156254A (hr) |
| NZ (2) | NZ598154A (hr) |
| PL (2) | PL2296464T3 (hr) |
| PT (2) | PT2807926T (hr) |
| RU (1) | RU2500665C2 (hr) |
| SI (2) | SI2807926T1 (hr) |
| TW (5) | TW202021946A (hr) |
| WO (1) | WO2009143509A1 (hr) |
| ZA (1) | ZA201008390B (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010525069A (ja) * | 2007-04-27 | 2010-07-22 | パラテック ファーマシューティカルズ インコーポレイテッド | アミノアルキルテトラサイクリン化合物の合成方法および精製方法 |
| WO2009111064A2 (en) | 2008-03-05 | 2009-09-11 | Paratek Pharmaceuticals, Inc. | Minocycline compounds and methods of use thereof |
| TW202021946A (zh) * | 2008-05-23 | 2020-06-16 | 美商派洛泰克藥物股份有限公司 | 四環素化合物之甲苯磺酸鹽及同素異形體 |
| ES2739626T3 (es) * | 2011-05-12 | 2020-02-03 | Paratek Pharm Innc | Sales cristalinas de amida del ácido (4S,4aS,5aR,12aS)-4-dimetilamino-3,10,12,12a-tetrahidroxi-7-[(metoxi(metil)amino)-metil]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahidro-naftacen-2-carboxílico y métodos de uso de las mismas |
| PT108223B (pt) * | 2015-02-13 | 2018-05-08 | Hovione Farm S A | Novas formas polimórficas de minociclina base e processos para a sua preparação |
| TW201705962A (zh) | 2015-03-23 | 2017-02-16 | 生物製藥Ｘ公司 | 皮膚用四環素醫藥組成物 |
| BR112018069303A2 (pt) * | 2016-03-24 | 2019-01-22 | Paratek Pharm Innc | método para tratamento de uma infecção |
| AU2017259960A1 (en) | 2016-05-02 | 2018-12-06 | Paratek Pharmaceuticals, Inc. | 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (UTI) treatment |
| KR102205843B1 (ko) * | 2016-06-22 | 2021-01-22 | 케이비피 바이오사이언시즈 씨오., 엘티디. | 9-아미노메틸 치환된 테트라사이클린 화합물의 결정형 및 그것의 제조 방법 |
| TWI746610B (zh) * | 2016-08-03 | 2021-11-21 | 美商派瑞泰Ｓｐｖ２有限公司 | 9-胺甲基米諾四環素化合物及其用途 |
| KR20190065315A (ko) * | 2016-10-03 | 2019-06-11 | 브리벤션 파마슈티컬 (상하이) 인크. | Trh 아날로그 및 아룬드산을 조합하여 이루어지는 조성물, 그리고 아룬드산의 약학적으로 허용되는 염 |
| US10383884B2 (en) | 2016-11-01 | 2019-08-20 | Paratek Pharmaceuticals, Inc. | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
| RU2632708C1 (ru) * | 2016-11-14 | 2017-10-09 | Лонг Шенг Фарма Лимитед | Способ получения комбинированного антибактериального препарата |
| CN111484424B (zh) * | 2020-04-14 | 2022-10-25 | 成都百特万合医药科技有限公司 | 一种合成奥马环素的方法 |
| AU2021288202A1 (en) * | 2020-06-11 | 2022-12-08 | Paratek Pharmaceuticals Inc. | Crystalline forms of omadacycline, methods of synthesis thereof and methods of use thereof |
| PT117254B (pt) | 2021-05-26 | 2024-04-18 | Hovione Farm S A | Método de síntese de compostos 9-aminometil tetraciclinas |
| CN113433249B (zh) * | 2021-07-21 | 2023-03-24 | 河北圣雪大成制药有限责任公司 | 一种高效液相色谱法检测米诺环素中间体有关物质的方法 |
| CN113929593B (zh) * | 2021-09-02 | 2024-05-31 | 河北圣雪大成唐山制药有限责任公司 | 一种土霉素-2,5-二羟基苯甲酸共晶及其制备方法 |
| WO2023047323A1 (en) * | 2021-09-24 | 2023-03-30 | Glenmark Life Sciences Limited | Process for the preparation of omadacycline tosylate |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2990331A (en) | 1956-11-23 | 1961-06-27 | Pfizer & Co C | Stable solutions of salts of tetracyclines for parenteral administration |
| US2980584A (en) | 1957-10-29 | 1961-04-18 | Pfizer & Co C | Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation |
| US3062717A (en) | 1958-12-11 | 1962-11-06 | Pfizer & Co C | Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation |
| US3019260A (en) | 1959-05-13 | 1962-01-30 | American Cyanamid Co | Process for the catalytic reduction of 6-hydroxy hydronaphthacenes |
| FR1430859A (hr) | 1960-05-23 | 1966-05-25 | ||
| US3165531A (en) | 1962-03-08 | 1965-01-12 | Pfizer & Co C | 13-substituted-6-deoxytetracyclines and process utilizing the same |
| DK122658B (da) * | 1963-06-17 | 1972-03-27 | Novo Terapeutisk Labor As | Fremgangsmåde til udfældning af tetracyclinbase i krystallinsk form. |
| US3454697A (en) | 1965-06-08 | 1969-07-08 | American Cyanamid Co | Tetracycline antibiotic compositions for oral use |
| US3304227A (en) | 1965-07-15 | 1967-02-14 | Loyal E Loveless | Antibiotic-containing animal feed |
| NL6607516A (hr) | 1966-05-31 | 1967-12-01 | ||
| DE1767891C3 (de) | 1968-06-28 | 1980-10-30 | Pfizer | Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat |
| NL158172B (nl) * | 1972-09-18 | 1978-10-16 | Farmaceutici Italia | Werkwijze voor het bereiden van tetracyclinederivaten met een substituent op de 7-plaats. |
| US3957980A (en) | 1972-10-26 | 1976-05-18 | Pfizer Inc. | Doxycycline parenteral compositions |
| DE2442829A1 (de) | 1974-09-06 | 1976-03-18 | Merck Patent Gmbh | Tetracyclische verbindungen und verfahren zu ihrer herstellung |
| US4018889A (en) | 1976-01-02 | 1977-04-19 | Pfizer Inc. | Oxytetracycline compositions |
| US4126680A (en) | 1977-04-27 | 1978-11-21 | Pfizer Inc. | Tetracycline antibiotic compositions |
| US4704383A (en) | 1983-12-29 | 1987-11-03 | The Research Foundation Of State University Of New York | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same |
| US4666897A (en) | 1983-12-29 | 1987-05-19 | Research Foundation Of State University | Inhibition of mammalian collagenolytic enzymes by tetracyclines |
| US4925833A (en) | 1983-12-29 | 1990-05-15 | The Research Foundation Of State University Of New York | Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis |
| USRE34656E (en) | 1983-12-29 | 1994-07-05 | The Research Foundation Of State University Of New York | Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency |
| US4935412A (en) | 1983-12-29 | 1990-06-19 | The Research Foundation Of State University Of New York | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same |
| JP3016587B2 (ja) | 1989-12-04 | 2000-03-06 | ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク | 非ステロイド抗炎症剤及びテトラサイクリンの配合 |
| US5308839A (en) | 1989-12-04 | 1994-05-03 | The Research Foundation Of State University Of New York | Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline |
| DE4031168A1 (de) | 1990-10-03 | 1992-04-16 | Degussa | Keramischer werkstoff zum verblenden von metallischem zahnersatz |
| US5770588A (en) | 1991-02-11 | 1998-06-23 | The Research Foundation Of State University Of New York | Non-antibacterial tetracycline compositions of the prevention and treatment of root caries |
| US5231017A (en) | 1991-05-17 | 1993-07-27 | Solvay Enzymes, Inc. | Process for producing ethanol |
| EP0536515B1 (en) | 1991-10-04 | 2001-12-19 | American Cyanamid Company | Novel 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines |
| US5494903A (en) | 1991-10-04 | 1996-02-27 | American Cyanamid Company | 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines |
| US5258371A (en) | 1992-05-29 | 1993-11-02 | Kuraray Co., Ltd. | Method to reduce connective tissue destruction |
| US6043225A (en) | 1992-06-12 | 2000-03-28 | Board Of Regents Of The University Of Washington | Diagnosis and treatment of arterial chlamydial granuloma |
| EP0599397B1 (en) | 1992-11-17 | 1996-08-28 | The Research Foundation Of State University Of New York | Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive collagen crosslinking during diabetes |
| US5523297A (en) | 1993-03-02 | 1996-06-04 | The Research Foundation Of State University Of New York | Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines |
| US6043231A (en) | 1993-03-02 | 2000-03-28 | The Research Foundation Of State Univ. Of New York | Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines |
| US5668122A (en) | 1993-07-28 | 1997-09-16 | Fife; Rose S. | Method to treat cancer with tetracyclines |
| JP2784847B2 (ja) | 1994-02-17 | 1998-08-06 | ファイザー インク． | ９−（置換アミノ）−アルファ−６−デオキシ−５−オキシテトラサイクリン誘導体、それらの製造及び、抗生物質としてのそれらの使用 |
| US5843925A (en) | 1994-12-13 | 1998-12-01 | American Cyanamid Company | Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth |
| US5834449A (en) | 1996-06-13 | 1998-11-10 | The Research Foundation Of State University Of New York | Treatment of aortic and vascular aneurysms with tetracycline compounds |
| US5827840A (en) | 1996-08-01 | 1998-10-27 | The Research Foundation Of State University Of New York | Promotion of wound healing by chemically-modified tetracyclines |
| US5789395A (en) | 1996-08-30 | 1998-08-04 | The Research Foundation Of State University Of New York | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production |
| US5919774A (en) | 1996-12-10 | 1999-07-06 | Eli Lilly And Company | Pyrroles as sPLA2 inhibitors |
| US5837696A (en) | 1997-01-15 | 1998-11-17 | The Research Foundation Of State University Of New York | Method of inhibiting cancer growth |
| US5773430A (en) | 1997-03-13 | 1998-06-30 | Research Foundation Of State University Of New York | Serine proteinase inhibitory activity by hydrophobic tetracycline |
| US6277067B1 (en) | 1997-04-04 | 2001-08-21 | Kerry L. Blair | Method and portable colposcope useful in cervical cancer detection |
| US5929055A (en) | 1997-06-23 | 1999-07-27 | The Research Foundation Of State University Of New York | Therapeutic method for management of diabetes mellitus |
| US6277061B1 (en) | 1998-03-31 | 2001-08-21 | The Research Foundation Of State University Of New York | Method of inhibiting membrane-type matrix metalloproteinase |
| US6015804A (en) | 1998-09-11 | 2000-01-18 | The Research Foundation Of State University Of New York | Method of using tetracycline compounds to enhance interleukin-10 production |
| US5977091A (en) | 1998-09-21 | 1999-11-02 | The Research Foundation Of State University Of New York | Method of preventing acute lung injury |
| US5998390A (en) | 1998-09-28 | 1999-12-07 | The Research Foundation Of State University Of New York | Combination of bisphosphonate and tetracycline |
| AU766200B2 (en) | 1998-11-18 | 2003-10-09 | Collagenex Pharmaceuticals, Inc. | Novel 4-dedimethy laminotetra cycline derivatives |
| DE19938198A1 (de) * | 1999-08-12 | 2001-03-01 | Deutsche Telekom Ag | Verfahren zum Etablieren eines gemeinsamen Schlüssels für eine Gruppe von mindestens drei Teilnehmern |
| US6231894B1 (en) | 1999-10-21 | 2001-05-15 | Duke University | Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase |
| US7231517B1 (en) * | 2000-03-03 | 2007-06-12 | Novell, Inc. | Apparatus and method for automatically authenticating a network client |
| KR100699390B1 (ko) * | 2000-07-07 | 2007-03-28 | 트러스티즈 오브 터프츠 칼리지 | 9-치환된 미노사이클린 화합물 |
| CN102336679A (zh) * | 2000-07-07 | 2012-02-01 | 塔夫茨大学信托人 | 7-取代的四环素化合物 |
| MXPA03008165A (es) | 2001-03-13 | 2003-12-12 | Paratek Pharm Innc | Compuestos tetraciclina sustituidos en la posicion 7,9. |
| US7553828B2 (en) | 2001-03-13 | 2009-06-30 | Paratek Pharmaceuticals, Inc. | 9-aminomethyl substituted minocycline compounds |
| WO2003004009A1 (en) * | 2001-07-02 | 2003-01-16 | Geneva Pharmaceuticals, Inc. | Pharmaceutical composition |
| EA200802365A1 (ru) | 2002-03-08 | 2009-08-28 | Паратек Фармасьютикалс, Инк. | Аминометилзамещенные тетрациклиновые соединения |
| JP4099039B2 (ja) * | 2002-11-15 | 2008-06-11 | 松下電器産業株式会社 | プログラム更新方法 |
| US20060287283A1 (en) * | 2003-07-09 | 2006-12-21 | Paratek Pharmaceuticals, Inc. | Prodrugs of 9-aminomethyl tetracycline compounds |
| JP4712325B2 (ja) * | 2003-09-12 | 2011-06-29 | 株式会社リコー | 通信装置、通信システム、通信方法及びプログラム |
| US8015399B2 (en) * | 2003-09-30 | 2011-09-06 | Ricoh Company, Ltd. | Communication apparatus, communication system, certificate transmission method and program |
| WO2005101727A1 (ja) * | 2004-04-15 | 2005-10-27 | Matsushita Electric Industrial Co., Ltd. | 通信装置、通信システム及び認証方法 |
| AR057649A1 (es) * | 2005-05-27 | 2007-12-12 | Wyeth Corp | Formas solidas cristalinas de tigeciclina y metodos para preparar las mismas |
| JP2009524675A (ja) * | 2006-01-24 | 2009-07-02 | パラテック ファーマシューティカルズ インコーポレイテッド | テトラサイクリンの経口バイオアベイラビリティーを増加する方法 |
| ES2528202T3 (es) * | 2006-04-24 | 2015-02-05 | Teva Pharmaceutical Industries Ltd. | Una forma cristalina de tigeciclina y procesos para su preparación |
| CN101134733A (zh) * | 2007-09-24 | 2008-03-05 | 合肥信风科技开发有限公司 | 一种替加环素的物质形态及其制备方法 |
| WO2009111064A2 (en) * | 2008-03-05 | 2009-09-11 | Paratek Pharmaceuticals, Inc. | Minocycline compounds and methods of use thereof |
| PT2271348T (pt) * | 2008-03-28 | 2018-04-16 | Paratek Pharm Innc | Formulação de comprimido oral de composto de tetraciclina |
| TW202021946A (zh) * | 2008-05-23 | 2020-06-16 | 美商派洛泰克藥物股份有限公司 | 四環素化合物之甲苯磺酸鹽及同素異形體 |
-
2009
- 2009-05-25 TW TW108126026A patent/TW202021946A/zh unknown
- 2009-05-25 TW TW110123796A patent/TW202216656A/zh unknown
- 2009-05-25 TW TW111139004A patent/TW202332671A/zh unknown
- 2009-05-25 TW TW098117308A patent/TWI585071B/zh active
- 2009-05-25 TW TW106103523A patent/TWI680117B/zh active
- 2009-05-26 PL PL09751737T patent/PL2296464T3/pl unknown
- 2009-05-26 JP JP2011510742A patent/JP5727930B2/ja active Active
- 2009-05-26 NZ NZ598154A patent/NZ598154A/xx unknown
- 2009-05-26 CA CA2724897A patent/CA2724897C/en active Active
- 2009-05-26 CN CN201510265009.XA patent/CN104844472B/zh active Active
- 2009-05-26 SI SI200932103T patent/SI2807926T1/sl unknown
- 2009-05-26 CA CA2987354A patent/CA2987354A1/en not_active Abandoned
- 2009-05-26 SI SI200931200T patent/SI2296464T1/sl unknown
- 2009-05-26 EP EP09751737.9A patent/EP2296464B1/en active Active
- 2009-05-26 CN CN201510647227.XA patent/CN105348138A/zh active Pending
- 2009-05-26 MX MX2010012622A patent/MX2010012622A/es active IP Right Grant
- 2009-05-26 EP EP14156670.3A patent/EP2807926B1/en active Active
- 2009-05-26 NZ NZ589574A patent/NZ589574A/en unknown
- 2009-05-26 MY MYPI2010005445A patent/MY156254A/en unknown
- 2009-05-26 ES ES14156670T patent/ES2842204T3/es active Active
- 2009-05-26 PT PT141566703T patent/PT2807926T/pt unknown
- 2009-05-26 ES ES09751737.9T patent/ES2538364T3/es active Active
- 2009-05-26 PL PL14156670T patent/PL2807926T3/pl unknown
- 2009-05-26 CN CN200980129398.6A patent/CN102105058B/zh active Active
- 2009-05-26 EP EP20200158.2A patent/EP3827817A1/en active Pending
- 2009-05-26 AR ARP090101875A patent/AR075447A1/es not_active Application Discontinuation
- 2009-05-26 AU AU2009248795A patent/AU2009248795B2/en active Active
- 2009-05-26 DK DK09751737.9T patent/DK2296464T3/en active
- 2009-05-26 US US12/471,758 patent/US8383610B2/en active Active
- 2009-05-26 LT LTEP14156670.3T patent/LT2807926T/lt unknown
- 2009-05-26 WO PCT/US2009/045143 patent/WO2009143509A1/en active Application Filing
- 2009-05-26 CN CN201810151302.7A patent/CN108324722A/zh active Pending
- 2009-05-26 HU HUE14156670A patent/HUE053038T2/hu unknown
- 2009-05-26 PT PT97517379T patent/PT2296464E/pt unknown
- 2009-05-26 KR KR1020107028820A patent/KR101679362B1/ko active IP Right Grant
- 2009-05-26 DK DK14156670.3T patent/DK2807926T3/da active
- 2009-05-26 BR BRPI0913026-8A patent/BRPI0913026B1/pt active IP Right Grant
- 2009-05-26 RU RU2010152758/04A patent/RU2500665C2/ru active
-
2010
- 2010-11-18 IL IL209414A patent/IL209414A0/en active IP Right Grant
- 2010-11-23 ZA ZA2010/08390A patent/ZA201008390B/en unknown
- 2010-12-20 MA MA33447A patent/MA32407B1/fr unknown
- 2010-12-22 CO CO10160851A patent/CO6300898A2/es not_active Application Discontinuation
- 2010-12-22 EC EC2010010704A patent/ECSP10010704A/es unknown
-
2011
- 2011-08-30 HK HK15105134.9A patent/HK1204526A1/xx unknown
- 2011-08-30 HK HK11109171.9A patent/HK1154757A1/xx unknown
-
2013
- 2013-01-24 US US13/749,101 patent/US9227921B2/en active Active
-
2015
- 2015-04-03 JP JP2015076659A patent/JP6129235B2/ja active Active
- 2015-06-02 HR HRP20150584TT patent/HRP20150584T1/hr unknown
- 2015-06-04 CY CY20151100497T patent/CY1116436T1/el unknown
- 2015-12-08 US US14/962,326 patent/US20160324879A1/en not_active Abandoned
-
2016
- 2016-11-23 AU AU2016262682A patent/AU2016262682B2/en active Active
-
2017
- 2017-04-11 JP JP2017077920A patent/JP2017149750A/ja active Pending
- 2017-09-21 US US15/711,502 patent/US20180104262A1/en not_active Abandoned
-
2018
- 2018-12-21 JP JP2018239471A patent/JP2019052184A/ja active Pending
-
2020
- 2020-10-23 JP JP2020177908A patent/JP2021011498A/ja active Pending
- 2020-12-29 CY CY20201101224T patent/CY1123705T1/el unknown
- 2020-12-31 HR HRP20202081TT patent/HRP20202081T1/hr unknown
-
2022
- 2022-10-21 JP JP2022169225A patent/JP2022189916A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150584T1 (hr) | Soli i polimorfi tetraciklinskog spoja | |
| HRP20200715T1 (hr) | Postupak proizvodnje n-[(3-aminooksetan-3-il) metil]-2-(1,1-diokso-3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina | |
| RU2015100280A (ru) | Многокомпонентные кристаллы, содержащие дазатиниб и определенные сокристаллобразователи | |
| ES2732360T3 (es) | Forma cristalina del 4-[5-(piridin-4-il)-1H-1,2,4-triazol-3-il]piridin-2-carbonitrilo | |
| KR101831535B1 (ko) | 무정형 형태의 다사티닙 염 | |
| HRP20201644T1 (hr) | Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba | |
| CA2985033C (en) | Crystalline form ii of 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1h-pyrazol-4-yl)-1h-imidazol-1-yl)-1hpyrazol0[3,4-b]pyridin-1-yl}benzamide | |
| CN110167550A (zh) | 西克里维罗甲磺酸盐的固体形式及其制备方法 | |
| HRP20120330T1 (hr) | Sukristali i farmaceutski pripravci koji ih sadrže | |
| BR112020000953A2 (pt) | polimorfos de 5-fluoro-4-imino-3-metil-1-tosil-3,4-di-hidropirimidin-2-ona | |
| CN104558093B (zh) | C21甾体皂苷苷元衍生物、其制备方法及其在制备抗肿瘤药物中的应用 | |
| ES2755396T3 (es) | Formas cristalinas de grapiprant | |
| RU2018145948A (ru) | Кристалл пирролопиримидина для получения jak-ингибитора | |
| KR20150139854A (ko) | 피롤 유도체의 결정 및 그 제조 방법 | |
| US20190270735A1 (en) | Polymorphs of Dasatinib | |
| HRP20211379T1 (hr) | Kristalni oblik antagonista gnrh receptora i postupak njegovog dobivanja | |
| ES2614997T3 (es) | Compuestos reguladores del crecimiento vegetal | |
| CN103965140A (zh) | 一种基于1,3,4-噻二唑的二硫醚类化合物及其制备方法和应用 | |
| HRP20161077T1 (hr) | Postupak proizvodnje metansulfonatnih soli ralfinamida ili njihovih r-enantiomera | |
| CN104447782A (zh) | 溴代去甲斑蝥素单酸苄酯及其合成方法和应用 | |
| HRP20211304T1 (hr) | Pripravljanje derivata 2-([1,2,3]triazol-2-il)-benzojeve kiseline | |
| Du et al. | Ethinyl estradiol cocrystals assembled by chain structures: Improvement in stability and solubility | |
| WO2014009970A2 (en) | Linagliptin solid dispersion | |
| GB2469883A (en) | Novel crystalline form of Prasugrel hydrogensulphate | |
| ES2912740T3 (es) | Compuesto heterocíclico y aplicación del mismo en medicina |